Yunpeng Yi

Dr. Yunpeng Yi

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 October 2022 in Nature Biotechnology
Verified
Journal Article
Closed access
PDF file
CLCong Liu
Cong Liu
HSHanxiao Sun
Hanxiao Sun
Yunpeng YiYunpeng Yi
Yunpeng Yi
WSWeiguo Shen
Weiguo Shen
KLKai Li
Kai Li
JWJing Wang
Jing Wang

22 January 2024 in Nature Protocols
Verified
Journal Article
Closed access
PDF file
WSWeiguo Shen
Weiguo Shen
HSHanxiao Sun
Hanxiao Sun
CLCong Liu
Cong Liu
Yunpeng YiYunpeng Yi
Yunpeng Yi
YHYongkang Hou
Yongkang Hou
CYChengqi Yi
Chengqi Yi

19 November 2014 in Molecules
Verified
Journal Article
Open access
PDF file
RSRuofeng Shang
Ruofeng Shang
GWGuan-Hua Wang
Guan-Hua Wang
XXXi-Ming Xu
Xi-Ming Xu
SLSi-Jie Liu
Si-Jie Liu
CZChao Zhang
Chao Zhang
YLYu Liu
Yu Liu
Several pleuromutilin derivatives possessing thiadiazole moieties were synthesized via acylation reactions under mild conditions. The in vitro antibacterial activities of the derivatives against methicillin-resistant S. aureus, methicillin-resistant S. epidermidis, S. aureus, S. epidermidis, E. coli, and B. cereus were tested by the agar dilution method and Oxford cup assay. All the screened compounds displayed potent activity. Compound 6d was the most active antibacterial agent because of its lowest MIC value and largest inhibition zone. Docking experiments were performed to understand the possible mode of the interactions between the derivatives and 50S ribosomal subunit. Moreover, the absorption, distribution, metabolism, excretion and toxicity properties of the synthesized compounds were analyzed after prediction using the Advanced Chemistry Development/Percepta Platform available online.

1 January 2017 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
Yunpeng YiYunpeng Yi
Yunpeng Yi
XXXiming Xu
Ximing Xu
YLYu Liu
Yu Liu
SXShuijin Xu
Shuijin Xu
XHXin Huang
Xin Huang
RSRuofeng Shang
Ruofeng Shang

Verified
Journal Article
Open access
PDF file
QWQiqi Wang
Qiqi Wang
BSBoyan Sun
Boyan Sun
Yunpeng YiYunpeng Yi
Yunpeng Yi
TVTony Velkov
Tony Velkov
JSJianzhong Shen
Jianzhong Shen
Haiyang JiangHaiyang Jiang
Haiyang Jiang
In modern pharmaceutical research and development (R&D), drug discovery remains a challenging process. Artificial intelligence (AI) has been extensively incorporated into various phases of drug discovery and development. AI enable effectively extract molecular structural features, perform in-depth analysis of drug–target interactions, and systematically model the relationships among drugs, targets, and diseases. These approaches improve prediction accuracy, accelerate discovery timelines, reduce costs from trial and error methods, and enhance success probabilities. This review summarizes recent advances in AI applications for drug design, including target identification, synthetic accessibility prediction, lead optimization, and ADMET property evaluation. Furthermore, it introduces various deep learning tools to guide researchers in selecting and implementing the most appropriate AI-driven strategies throughout the drug discovery process. We hope it can establish a conceptual framework intended to advance AI-driven methodologies in pharmaceutical research by comprehensively organizing novel perspectives and critical insights.

11 January 2023 in Bioorganic Chemistry
Verified
Journal Article
Closed access
Yunpeng YiYunpeng Yi
Yunpeng Yi
SYShifa Yang
Shifa Yang
YLYueyue Liu
Yueyue Liu
BYBin Yin
Bin Yin
ZZZengcheng Zhao
Zengcheng Zhao
LSLin Shuqian
Lin Shuqian